BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cascini C, Chiodoni C. The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response. Cells 2021;10:1668. [PMID: 34359840 DOI: 10.3390/cells10071668] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhong Y, Zhang Y, Wei S, Chen J, Zhong C, Cai W, Jin W, Peng H. Dissecting the effect of sphingolipid metabolism gene in progression and microenvironment of osteosarcoma to develop a prognostic signature. Front Endocrinol 2022;13:1030655. [DOI: 10.3389/fendo.2022.1030655] [Reference Citation Analysis]
2 Pan R, Pan F, Zeng Z, Lei S, Yang Y, Yang Y, Hu C, Chen H, Tian X. A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy. Front Immunol 2022;13:1017120. [DOI: 10.3389/fimmu.2022.1017120] [Reference Citation Analysis]
3 Tan J, Feng X, Wu H, Yang B, Shi M, Xie C, Su Z, Li L, Luo M, Zuo Z, Zhu S, Yang J, Lin L, Cui D. Characterization of the Tumor Microenvironment in Osteosarcoma Identifies Prognostic- and Immunotherapy-Relevant Gene Signatures. Journal of Immunology Research 2022;2022:1-25. [DOI: 10.1155/2022/6568278] [Reference Citation Analysis]
4 Sajjadi E, Gaudioso G, Terrasi A, Boggio F, Venetis K, Ivanova M, Bertolasi L, Lopez G, Runza L, Premoli A, Lorenzini D, Guerini-rocco E, Ferrero S, Vaira V, Fusco N. Osteoclast-like stromal giant cells in breast cancer likely belong to the spectrum of immunosuppressive tumor-associated macrophages. Front Mol Biosci 2022;9:894247. [DOI: 10.3389/fmolb.2022.894247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yang M, Zheng H, Xu K, Yuan Q, Aihaiti Y, Cai Y, Xu P. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA. Front Immunol 2022;13:919231. [DOI: 10.3389/fimmu.2022.919231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Liu W, Hao Y, Tian X, Jiang J, Qiu Q. The Role of NR4A1 in the Pathophysiology of Osteosarcoma: A Comprehensive Bioinformatics Analysis of the Single-Cell RNA Sequencing Dataset. Front Oncol 2022;12:879288. [DOI: 10.3389/fonc.2022.879288] [Reference Citation Analysis]
7 Pearson AD, Gaspar N, Janeway K, Campbell-Hewson Q, Lawlor ER, Copland C, Karres D, Norga K, Benzaghou F, Weiner S, Weigel B, Weiss AR, Strauss SJ, Smith M, Setty BA, Seibel N, Scobie N, Pappo A, Okpara CE, Nysom K, McDonough J, Marshall LV, Ludwinski D, Ligas F, Lesa G, Knudsen S, Kauh J, Hsieh A, Heenen D, Hawkins DS, Graham A, Garmey E, DuBois SG, Fox E, Donoghue M, de Rojas T, Chung J, Casanova M, Brennan B, Bishop M, Buenger V, Reaman G, Vassal G. Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer 2022;173:71-90. [PMID: 35863108 DOI: 10.1016/j.ejca.2022.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Lama S, Luce A, Bitti G, Chacon-Millan P, Itro A, Ferranti P, D'Auria G, Cammarota M, Nicoletti GF, Ferraro GA, Schiraldi C, Caraglia M, Amler E, Stiuso P. Polydatin Incorporated in Polycaprolactone Nanofibers Improves Osteogenic Differentiation. Pharmaceuticals (Basel) 2022;15:727. [PMID: 35745646 DOI: 10.3390/ph15060727] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Pang H, Wu T, Peng Z, Tan Q, Peng X, Zhan Z, Song L, Wei B. Baicalin induces apoptosis and autophagy in human osteosarcoma cells by increasing ROS to inhibit PI3K/Akt/mTOR, ERK1/2 and β-catenin signaling pathways. Journal of Bone Oncology 2022;33:100415. [DOI: 10.1016/j.jbo.2022.100415] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Qin Z, Luo K, Liu Y, Liao S, He J, He M, Xie T, Jiang X, Li B, Liu H, Huang Q, Tang H, Feng W, Zhan X. ATG16L1 is a Potential Prognostic Biomarker and Immune Signature for Osteosarcoma: A Study Based on Bulk RNA and Single-Cell RNA-Sequencing. IJGM 2022;Volume 15:1033-45. [DOI: 10.2147/ijgm.s341879] [Reference Citation Analysis]